Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1201 in MAGE-A4-expressing solid tumors
NCT02096614Phase 1Completed
- Sponsor
- Mie University
- Start
- Apr 2014
- Primary completion
- Mar 2021
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TBI-1201 in solid tumor (4 arms), sponsored by Mie University. Primary endpoints: Incidence and grade of adverse events (CTCAE) at 8 weeks, Appearance of replication competent retrovirus by PCR at 8 weeks and 2 more. Started Apr 2014; status: completed.
02
Drugs
TBI-1201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02096614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096614.